Clinicians need up-to-date information on patient selection for active surveillance and the recommended active surveillance protocol, so that appropriate men with prostate cancer can be encouraged to pursue active surveillance and avoid treatment and side effects. In addition, clinicians must be aware of results of recent clinical trials in the non-metastatic CRPC setting, so that patients can receive optimal care and delay the onset of metastases as long as possible.